Panacea Biotec Ltd

AGM details

• Held on Sep 29, 2026 at 11:30 A.M. via Video Conferencing.
• Deemed venue at registered office; meeting conducted through VC.
• Remote e-voting: Sep 26–28, 2026; cut-off Sep 22, 2026.
• Voting results to be declared by Oct 1, 2026.

Ordinary resolutions

• Adopt standalone financial statements for year ended March 31, 2026.
• Adopt consolidated financial statements for year ended March 31, 2026.
• Re-appoint retiring director Ankesh Jain.
• Re-appoint retiring director Harshet Jain.

Special resolutions

• Appointment of Rajinder Singh Manku as independent director.
• Ratify remuneration of Cost Auditors for 2026-27.

Auditors

• Statutory auditors attended; no qualifications reported.

Filing Status

• Two IT Demand Orders under Section 156 total ₹4.32 crore.
• Demands relate to AY 2022-23 and 2023-24; company to appeal.

Key Update

• Four IT demand orders dated 25 Sep 2026 totaling ₹9.82 crore issued by Delhi IT dept.
• Penalties for alleged misreporting/under-reporting of income under Section 270A.
• Assessment years affected: 2014-15 to 2016-17 and 2018-19.
• Company disputes demand; intends to appeal; no significant financial or operational impact expected.

Panacea Biotec Ltd — Trading window shall remain closed for all Designated Persons from October 01, 2026 till completion of 48 hours from the announcement of the unaudited financial results of the Company for the quarter and half year ending September 30, 2026

KYC updation for physical shareholders

• Reminder letters issued to physical shareholders to update PAN, KYC, bank details, and contact information.
• Updation enables electronic payments; non-updated folios restrict RTA service access.

Dematerialisation and KYC forms

• Company urges conversion of physical holdings to demat; assistance offered by RTA and company.
• Forms ISR-1, ISR-2, SH-13, ISR-3, SH-14 and related details are published on company and RTA sites.

AGM details and governance updates

• 42nd AGM scheduled for September 29, 2026, via VC/OAVM, with no physical venue.
• Register of Members and share transfer books will be closed Sep 25–29, 2026.
• Ordinary business: adoption of standalone and consolidated financial statements for year ended March 31, 2026.
• Re-appointment of Ankesh Jain and Harshet Jain as directors (retire by rotation).
• Special business: appointment of Rajinder Singh Manku as independent director for 5 years from July 1, 2026.
• Cost Auditors remuneration: ₹1,25,000 for 2026-27 to M/s Jain Sharma & Associates, plus GST.
• Record date for voting: Aug 28, 2026; remote e-voting: Sep 26–28, 2026; AGM voting: Sep 29, 2026.

AGM notice and e-voting details

• 42nd AGM on Sept 29, 2026 at 11:30 IST via VC/OAVM
• Notice and annual report for FY2025-26 sent to registered emails
• Access via provided AGM and annual report web-links
• Remote e-voting from Sept 26, 2026 9:00 to Sept 28, 2026 17:00 IST
• Remote e-voting cut-off date: Sept 22, 2026
• Compliance with MCA/SEBI circulars for AGM proceedings

Shareholder information and KYC

• Unregistered email holders instructed to access notice via web-links
• To receive communications, update email with Depository Participant or RTA
• RTA: Skyline Financial Services Private Limited (Unit: Panacea Biotec Limited)
• KYC contact: kyc@skylinerta.com

Overview

• Pharmaceuticals manufacturer; standalone BRSR for FY2025-26.
• Exports account for about 65% of turnover across ~37 countries.
• About 1,500 employees; three plants and two offices in India.

Key ESG Risks & Opportunities

• Product quality and safety risk with potential penalties or supply disruption.
• Mitigations include cGMP, GLP, pharmacovigilance, SOPs, and vendor reviews.
• Cybersecurity risk addressed by IT security upgrades and staff awareness.
• Climate action through decarbonization, water-use assessments, and waste reduction targets.
• R&D and human capital development present growth opportunities.

Governance & Policy Highlights

• Board oversight via a Risk Management Committee; ESG framework under development.
• Policies cover anti-corruption, supplier code, whistleblower, and POSH.
• Certifications include ISO 14001, ISO 45001, GMP; UNGP/UNGC alignment.
• Assurance: BRSR reported on a standalone basis; no external assurance obtained.

Social Responsibility & Workforce

• Total employees around 1,500; board size 11 with 9.09% female representation.
• LTIFR is nil for both employees and workers.
• 100% health insurance coverage; comprehensive EHS training for all staff.
• CSR turnover ₹4,134.92 million; net worth negative.
• Vaccines and health solutions reached over 50 million babies in LMICs.
• Recognized with Incredible Workplaces Gold (2025) and Vision Zero India Safety Rating (2024).

Environmental Performance

• Total energy use 220,192.8 GJ; renewables 101,149.56 GJ; non-renewables 119,043.24 GJ.
• Energy intensity: 53.25 GJ per ₹1M turnover.
• Scope 1 emissions: 3,303.32 tCO2e; Scope 2: 20,324.32 tCO2e.
• Total Scope 1+2: 23,627.64 tCO2e; intensity 5.71 tCO2e per ₹M turnover.
• Water withdrawal 1,87,457 kL; water intensity 45.34 kL per ₹M turnover.
• Zero Waste to Landfill in India targeted by end-2026.
• Total waste generated: 1,113 metric tonnes; disposal includes incineration 38.14 t and landfilling 12.33 t.
• Plastic waste recycled 0.40 t; reuse 0.80 t; EPR-compliant plastic waste collection and recycling.
• Facilities are ISO 14001 and ISO 45001 certified.

Stakeholder Engagement & Complaints

• Stakeholders: employees, shareholders, customers, suppliers, government, communities.
• Engagement channels include meetings, emails, and website communications with varying frequency.
• Customer complaints: 2 filed in FY2025-26; 10 in FY2024-25.
• POSH complaints: 1 in FY2025-26; none in FY2024-25.
• Grievance mechanisms accessible via the company website.

Other Notable Metrics

• Exports comprise about 65% of turnover; ~37 international markets.
• Affiliations with 7 trade associations, including Indian Pharmaceutical Alliance and DCVMN.
• No adverse orders on anti-competitive conduct in FY2025-26.
• Cyber security framework in place; no data breaches reported.
• BRSR is reported on a standalone basis; no external assurance obtained.